Get informed when a big investor buys or sells
+ FollowOvervalued by 21.4% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $9.86 Million |
|---|---|
| Enterprise Value | $8.69 Million |
| Earnings per Share | $-0.03 |
| Beta | 0.29 |
| Outstanding Shares | 277,748,003 |
| P/E Ratio | -2.18 |
|---|---|
| PEG | 4.73 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.27 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.18 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined...